NCT02437539View on ClinicalTrials.gov

Evaluation of a New Radiotracer (68Ga-NOTA-AE105) for Diagnosing Aggressive Cancer With Positron Emission Tomography

PHASE1CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

May 31, 2015

Primary Completion Date

August 31, 2015

Study Completion Date

August 31, 2015

Conditions
Breast CancerProstate CancerUrinary Bladder Cancer
Interventions
DRUG

Injection of 68Ga-NOTA-AE105

One injection of 68Ga-NOTA-AE 105

DEVICE

Positron Emission Tomography scans

Following injection of 68Ga-NOTA-AE105 the patients will be PET scanned at 10 minutes, 1 hour and 2 hours post injection

Trial Locations (1)

2100

Department of Clinical Physiology, Nuclear Medicine and PET, Rigshospitalet, Copenhagen

Sponsors

Collaborators (1)

Curasight
All Listed Sponsors
collaborator

Curasight

INDUSTRY

lead

Rigshospitalet, Denmark

OTHER

NCT02437539 - Evaluation of a New Radiotracer (68Ga-NOTA-AE105) for Diagnosing Aggressive Cancer With Positron Emission Tomography | Biotech Hunter | Biotech Hunter